In a significant move to fortify the nation’s healthcare, the Biden-Harris Administration has unveiled a series of proposals to enhance the 2025 Medicare Advantage and Medicare Prescription Drug Benefit Program (Part D). These strategic measures, integral to President Biden’s broader healthcare agenda, signify a commitment to fostering competition, lowering costs, and ensuring every American has access to high-quality, affordable healthcare.
Preventing Predatory Marketing
One of the key focuses of the proposed rules is to combat anti-competitive practices in steering prospective Medicare enrollees. The administration aims to achieve this by addressing the compensation structures of agents and brokers and introducing guardrails to ensure plans prioritize the best interests of enrollees.
Enhancing Behavioral Health Care Access
Recognizing the importance of mental health and substance use disorder treatment, the administration proposes an expansion of the Medicare Advantage network. This includes adding various behavioral health provider types to meet the evolving needs of beneficiaries.
Improving Supplemental Benefits
The administration proposes personalized mid-year notifications to Medicare Advantage enrollees about their unused benefits to make supplemental benefits more impactful. This not only encourages higher utilization but also ensures that these benefits align with the unique healthcare needs of individuals.
Addressing Prior Authorization Policies
Acknowledging concerns about policies hindering access for underserved populations, the administration introduces measures to include health equity experts on utilization management committees. An annual health equity analysis and public disclosure of its impact on vulnerable populations aim to promote transparency.
Promoting Health Equity
The proposed streamlining of enrollment options for individuals with both Medicare and Medicaid is a step towards fostering integrated care. This move is aligned with the broader goal of promoting health equity in policy and enrollment processes.
Advancing the Prescription Drug Marketplace
To support competition in the prescription drug marketplace, CMS proposes flexibility in substituting biosimilar biological products in Part D plans. This move ensures timely access to cost-effective biosimilar drugs for Medicare beneficiaries.
Comment Period and Stakeholder Engagement
Recognizing the importance of public input, the proposed rules are open for a 60-day comment period, allowing stakeholders to provide valuable feedback. This inclusive approach aims to gather diverse perspectives and refine the proposals for optimal impact.
Transparent and Accountable Healthcare Initiatives
These proposals align with the administration’s commitment to transparent, affordable, and accountable healthcare. By emphasizing competition, protecting enrollees, and elevating the quality of healthcare coverage, the Biden-Harris Administration aims to usher in a new era of healthcare resilience and accessibility.
The Biden-Harris Administration’s proposed measures signify a comprehensive effort to strengthen Medicare Advantage and the Medicare Prescription Drug Benefit Program. By addressing issues such as predatory marketing, improving access to behavioral health care, enhancing supplemental benefits, and promoting transparency, the administration aims to create a competitive and equitable healthcare landscape. The proposed changes underscore a commitment to affordability, transparency, and quality in healthcare coverage, aligning with the broader healthcare goals of the administration.
Follow us for latest updates.
Table of Contents